MIRECA
The Minimally Invasive Rectal Carcinoma Surgery Study Group (MIRECA) is a Dutch collective of over 30 colorectal surgeons from both academic and non-academic institutions, united by a shared commitment to advancing the surgical treatment of rectal carcinoma. Established in 2020, our group is dedicated to optimizing the care and surgical outcomes for patients with rectal cancer.
Since its inception, MIRECA has published and presented numerous studies on rectal cancer treatment at both national and international colorectal conferences. Currently, we are involved in numerous research projects focusing on various aspects of rectal cancer care, including (neo)adjuvant therapies, postoperative outcomes, quality of life, and cost-effectiveness. Among our initiatives is the VANTAGE-trial, a national multicenter prospective cohort study that involves over 45 dedicated centers across the Netherlands.
Our Mission
MIRECA is committed to regularly sharing the findings of our research projects. Our group holds a prominent position in national leadership, with representation from current and former chairs of the Dutch Society for Endoscopic Surgery and the Dutch Society of Colorectal Surgery. Additionally, our members oversee important initiatives such as the international TaTME registry and the national TAMIS course.
At MIRECA, we aim to optimize the surgical treatment of rectal cancer, coordinate and advance research projects, provide a platform for knowledge exchange, and enhance the implementation and revision of clinical guidelines.
At MIRECA, we aim to optimize the surgical treatment of rectal cancer, coordinate and advance research projects, provide a platform for knowledge exchange, and enhance the implementation and revision of clinical guidelines.
Centers
